Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ian Hirsch"'
Publikováno v:
Annals of Allergy, Asthma & Immunology. 125:171-176
Background Blood eosinophil count (BEC) measurements are a noninvasive, relatively reliable surrogate marker for eosinophilic airway inflammation. Single measurements of peripheral BEC greater than or equal to 150 cells/μL predict the response to an
Publikováno v:
Annals of Allergy, Asthma & Immunology. 124:79-86
Background Fixed airflow obstruction (FAO) is associated with severe eosinophilic asthma. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody for patients with severe, uncontrolled eosinophilic asthma. Objective W
Publikováno v:
Advances in Therapy
Introduction For patients with eosinophilic asthma with allergic characteristics, understanding the key drivers of exacerbations is important to identify optimal treatment strategies. Benralizumab is an interleukin-5 receptor alpha–directed cytolyt
Autor:
David J. Jackson, Hassan Burhan, Andrew Menzies-Gow, Paul Pfeffer, Alexandra Nanzer, Esther Garcia Gil, Tamsin Morris, Trung N. Tran, Ian Hirsch, Sabada Dube
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:1534-1544.e4
Benralizumab is an IL-5 receptor alpha-directed cytolytic mAb that depletes eosinophils, reducing exacerbations and oral corticosteroid (OCS) use, and improves asthma control for patients with severe eosinophilic asthma (SEA). Data on response in pat
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma
Autor:
Gary T. Ferguson, James Zangrilli, Ian Hirsch, Joel N. Kline, Njira L Lugogo, Frank Trudo, Mitchell Goldman, Geoffrey Chupp
Publikováno v:
Annals of Allergy, Asthma & Immunology. 122:478-485
Background Benralizumab is a unique eosinophil-depleting monoclonal antibody that significantly reduces asthma exacerbations, improves lung function and asthma symptoms, and permits the reduction of maintenance oral corticosteroid dosage for patients
Autor:
Ian D. Pavord, Malin Fagerås, Mitchell Goldman, J. Mark FitzGerald, Gene L. Colice, Guy Brusselle, Matthew Keith, Ian Hirsch, Esther Garcia Gil, Monica Kraft
Publikováno v:
EUROPEAN RESPIRATORY JOURNAL
BackgroundGreater precision in asthma exacerbation risk prediction may improve outcomes. We sought to identify clinical characteristics and biomarkers associated with elevated exacerbation risk in patients with severe, uncontrolled asthma.MethodsData
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75a5997d3a606a74141bc00eafa5d19
https://biblio.ugent.be/publication/8714420
https://biblio.ugent.be/publication/8714420
Autor:
J. Mark FitzGerald, Andrew Menzies-Gow, Paul Newbold, Paul Metcalfe, James Zangrilli, Ian Hirsch, Mitchell Goldman, Eugene R. Bleecker
Publikováno v:
The Lancet. Respiratory medicine. 6(1)
Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma. We further explored the
Publikováno v:
Current medical research and opinion. 33(9)
Objective: Benralizumab, an anti-eosinophilic monoclonal antibody, in combination with high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS/LABA), significantly reduced asthma exacerbations, improved lung function, and reduced sympto
Autor:
Paul Newbold, Mitchell Goldman, J. Mark FitzGerald, Ian Hirsch, Yanping Wu, Eugene R. Bleecker, Michael E. Wechsler, James Zangrilli, Andrew Menzies-Gow
Publikováno v:
European Respiratory Journal. 52:1800936
Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab e
Publikováno v:
Annals of Allergy, Asthma & Immunology. 120:504-511.e4
Background Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody indicated for add-on maintenance treatment of patients with severe asthma aged 12 years